Journal of Capital Medical University ›› 2013, Vol. 34 ›› Issue (1): 11-17.doi: 10.3969/j.issn.1006-7795.2013.01.003

Previous Articles     Next Articles

Synthesis and biodistribution of 18F-labeled pyridyl pyridaben analogues

MOU Tiantian1, ZHANG Xianzhong2, WANG Qian1, PENG Cheng3, MA Yunchuan3, MI Hongzhi1   

  1. 1. Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China;
    2. Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361005, China;
    3. PET Center of Xuanwu Hospital, Capital Medical University, Beijing 100053, China
  • Received:2012-12-06 Online:2013-02-21 Published:2013-02-25
  • Supported by:

    This study was supported by National Natural Science Foundation of China (20871020, 81271613, 21271030) and Natural Science Foundation of Beijing (2092018).

Abstract:

Objective A fluorine-18 labeled pyridazinone derivative: 4-chloro-2-tert-butyl-5-[6-[4-[2-[2-[2-[18F]fluroethoxy]ethoxy]ethoxy]-1H-1,2,3-triazol-1-yl]methyl]-2-pyridinyl]methoxy]-3(2H)-pyridazinone ([18F]FPTP-P3) was designed and prepared, and its potential as a myocardial perfusion imaging agent was evaluated. Methods [18F]FPTP-P3 was prepared by substituting tosyl of precursor with 18F. The tracer was evaluated by stability study, octanol/water partition coefficient and biodistribution study. Results The total radio-synthesis time was 70-90 min, typical decay-corrected radiochemical yield was 36±5.6%, and the radiochemical purity (RCP) was>98% after purification. It is a lipophilic compound, and stable in water for 3 h. The results of biodistribution study in mice showed that [18F]FPTP-P3 had certain initial heart uptake and the clearance of liver was very fast as well. However the retention of heart uptake was not ideal.Conclusion [18F]FPTP-P3 is not suitable for heart imaging in vivo.

Key words: [18F]FPTP-P3, pyridaben, heart uptake, biodistribution

CLC Number: